法玛新治疗中晚期恶性肿瘤的临床观察  

Clinical Study of Pharmorubicin in Patients with Advanced Tumors

作　　者：江伟[1] 潘良熹[1] 冯继峰[1] 陈嘉[1] 

机构地区：[1]江苏省肿瘤防治研究所内科,江苏南京210009

出　　处：《河南肿瘤学杂志》2002年第1期20-22,共3页Henan Journal of Oncology

摘　　要：目的　验证合资产品法玛新 (EPI)治疗非霍奇金淋巴瘤 (NHL)和乳腺癌的疗效和安全性。方法　乳腺癌 :5 -Fu 5 0 0mg/m2ivgttd1,EPI 60mg/m2 ivd1,CTX 60 0mg/m2 ivd1;NHL :CTX 60 0mg/m2 ivd1,EPI 60mg/m2 ivd1,VCR 1.4mg/m2 ivdl,PDN 60mg/m2 pod1～ 5。 2 1天为 1周期 ,治疗 2周期。结果　本组 3 0例中 ,总有效率 (CR +PR) 67%。NHL的疗效为 75 % ,其中CR 5例 ,占 2 5 %。乳腺癌的有效率为 5 0 % ,CR 1例 ,占 10 %。毒性主要表现为骨髓抑制和脱发 ,白细胞计数下降发生率两周期分别为 90 %和 93 % ,Ⅲ～Ⅳ度分别为 3 3 4%和 2 6 7%。消化道反应轻微 ,未发现肝肾功能及心电图 (EKG)异常。Objective In order to examine the effort and security of pharmorubcin(EPI) which is made by joint venture enterprise in the treatment of patients with non-hodgkin lyphoma(NHL) and breast cancer.Methods In breast cancer group,patients received 5-Fu 500 mg/m 2 ivgtt d 1,EPI 60 mg/m 2 iv d l,CTX 6000 mg/m 2 iv d 1;NHL:EPI 60 mg/m 2 iv d 1,CTX600 mg/m 2 iv d 1,CVR 1.4 mg/m 2 iv d l,PDN 60 mg/m 2 d 1～5 .Both groups were repeated every 21 days for two cycles.Results The objective response rate(CR+PR) was 67% in all the 30 cases.The objective response rate was 75% in NHL group compared to 50% in breast cancer group.Complete response was 25% in NHL group compared to 10% in breast cancer group.Toxicities include myelosuppression and trichomadesis.The rate of decline of WBC was 90% in NHL group and 93% in breast cancer group and especially in grade Ⅲ and Ⅳ myelosuppression was 33.4% and 26.7%.The response of alimentary was trivial and there was no evidence of abnormality in liver and kidney functions.Conclusions Pharmorubcin(EPI) is of more effect and security.

关 键 词：法玛新 非霍奇金淋巴瘤 乳腺癌 联合化疗 治疗 

分 类 号：R730.53[医药卫生—肿瘤]